HOME > NATION > Article

Text Size

small

medium

large


European Agency Switches to Recommending New Alzheimer's Drug

European Agency Switches to Recommending New Alzheimer's Drug

   London, Nov. 14 (Jiji Press)--The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval of sales of lecanemab to treat Alzheimer's disease.
   The committee of the pharmaceuticals watchdog had shown a negative opinion in July on the medicine, developed by drugmakers Eisai Co. of Japan and Biogen Inc. of the United States.
   After conducting a re-examination as requested by the pair, however, the committee judged that the efficacy of the medicine outweighs the risk for some patients.
   If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the European Union region.
   According to the EMA, the recommendation excludes patients who carry two copies of the ApoE4 gene, considering higher risk of side effects such as swelling and bleeding in the brain.

To read a full story, please click here to find out how to subscribe.

NATION

HEADLINES

POLITICS
Japan Diet to Be Convened into 24-Day Extra Session on Nov. 28
ECONOMY
Indian Visitors to Japan Increase 29.1% to Record 21,700 in Oct.
SPORTS
MLB: Tigers' Tarik Skubal, Braves' Chris Sale Named Cy Young Award Winners
OTHER
30% of Children in Poor Families in Japan Find School Not Fun: Survey

AFP-JIJI PRESS NEWS JOURNAL


Photos